drugset / Trial / NCT02451098

Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

NCT02451098

Phase 3 Completed 385 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Factorial Design, Phase III Clinical Trial.

Timeline

Start
2015-03
Primary completion
2015-10
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 10 mg
Subject Atorvastatin Small molecule 20 mg
Subject Atorvastatin Small molecule 40 mg
Subject Ezetimibe Unknown 10 mg

Indications